{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:10:07Z","timestamp":1771931407711,"version":"3.50.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Endothelial injury is a major contributor to morbidity and mortality in pediatric patients undergoing hematopoietic cell transplantation (HCT). It appears as sinusoidal obstruction syndrome (SOS) or transplant-associated thrombotic microangiopathy (TMA), among other conditions. Composite indices like the Endothelial Activation and Stress Index (EASIX) and its modified version (m-EASIX) may serve as accessible biomarkers for early identification. However, their utility in pediatric populations is unestablished. We aimed to explore whether EASIX and m-EASIX can help identify endothelial complications in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective, single-center observational cohort study of 31 children and young adults undergoing HCT. Serial measurements of EASIX and m-EASIX scores, based on standard laboratory parameters, were collected at baseline and at multiple post-HCT time points (Days 0, 7, 14, 21, 28, and 100).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Within 100 days after HCT, SOS and\/or TMA developed in six patients. At Day 21, EASIX and m-EASIX scores were significantly higher in children with endothelial complications than in controls. The m-EASIX score also showed predictive value at Day 14. Receiver operating characteristic analysis showed discrimination at Day 21 for both scores (AUCs of 0.807 for EASIX and 0.865 for m-EASIX). Changes from baseline to Day 21 further improved accuracy, with thresholds achieving high sensitivity for screening patients at increased risk of SOS and\/or TMA. The Day 21 landmark is most relevant for identifying patients at risk of later-onset or persistent endothelial injury, which remains clinically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that EASIX and m-EASIX may serve as practical and dynamic biomarkers for detecting endothelial injury in pediatric HCT recipients. The observation that Day 21 scores and their changes from baseline correlate with later complications highlights a potential window for risk stratification. However, these results should be interpreted cautiously, given the single-center design and limited sample size. Further research is needed to confirm whether these indices can reliably guide clinical decisions across diverse settings. Exploring their use in populations where reduced-intensity conditioning (RIC) and alternative donors are standard could provide important insights. Multicenter studies will be essential to validate these preliminary observations and refine biomarker-based strategies for post-HCT care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1742467","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:22:25Z","timestamp":1770787345000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Detecting Endothelial Compromise Objectively through Dynamic EASIX scoring (DECODE) - predictive utility of EASIX and modified EASIX scores for endothelial complications post hematopoietic cell transplant"],"prefix":"10.3389","volume":"16","author":[{"given":"Saad","family":"Ghafoor","sequence":"first","affiliation":[{"name":"Department of Pediatric Medicine, Division of Critical Care Medicine, St. Jude Children\u2019s Research Hospital","place":["Memphis, TN, United States"]},{"name":"Department of Pediatrics, Division of Pediatric Critical Care, University of Tennessee Health Science Center","place":["Memphis, TN, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Pediatric Medicine, Division of Critical Care Medicine, St. Jude Children\u2019s Research Hospital","place":["Memphis, TN, United States"]},{"name":"Department of Pediatrics, Division of Pediatric Critical Care, University of Tennessee Health Science Center","place":["Memphis, TN, United States"]},{"name":"Department of Pediatrics, Division of Pediatric Critical Care, University of Utah","place":["Salt Lake City, UT, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"McArthur","sequence":"additional","affiliation":[{"name":"Department of Pediatric Medicine, Division of Critical Care Medicine, St. Jude Children\u2019s Research Hospital","place":["Memphis, TN, United States"]},{"name":"Department of Pediatrics, Division of Pediatric Critical Care, University of Tennessee Health Science Center","place":["Memphis, TN, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Avent","sequence":"additional","affiliation":[{"name":"Department of Pediatric Medicine, Division of Critical Care Medicine, St. Jude Children\u2019s Research Hospital","place":["Memphis, TN, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Wei","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, St. Jude Children\u2019s Research Hospital","place":["Memphis, TN, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, St. Jude Children\u2019s Research Hospital","place":["Memphis, TN, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lama","family":"Elbahlawan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Medicine, Division of Critical Care Medicine, St. Jude Children\u2019s Research Hospital","place":["Memphis, TN, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000143","article-title":"Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions","volume":"3","author":"Pagliuca","year":"2019","journal-title":"Blood Adv"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01607-8","article-title":"Early vascular toxicity after pediatric allogeneic hematopoietic stem cell transplantation","volume":"57","author":"Leimi","year":"2022","journal-title":"Bone Marrow Transpl"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030680","article-title":"Endothelial dysfunction syndromes after allogeneic stem cell transplantation","volume":"15","author":"Vythoulkas","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011078","article-title":"Pediatric transplant-associated thrombotic microangiopathy health care utilization and implications of eculizumab therapy","volume":"8","author":"Schoettler","year":"2024","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"53","author":"Corbacioglu","year":"2018","journal-title":"Bone Marrow Transpl"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01265-2","article-title":"A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease\/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study","volume":"56","author":"Mohty","year":"2021","journal-title":"Bone Marrow Transpl"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003988","article-title":"Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis","volume":"5","author":"Higham","year":"2021","journal-title":"Blood Adv"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1399696","article-title":"Transplant-associated thrombotic microangiopathy in pediatrics: incidence, risk factors, therapeutic options, and outcome based on data from a single center","volume":"14","author":"Kafa","year":"2024","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007635","article-title":"Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study","volume":"12","author":"Penack","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14197105","article-title":"Unraveling the Easix score: its association with vasopressor need in critically ill septic pediatric hematology-oncology patients","volume":"14","author":"Elbahlawan","year":"2025","journal-title":"J Clin Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-022-01623-0","article-title":"Preconditioning Modified-Easix as a predictor of prognosis in allogeneic hematopoietic stem cell transplant recipients","volume":"39","author":"Yegin","year":"2023","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007381","article-title":"Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation","volume":"6","author":"Nawas","year":"2022","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.11.015","article-title":"Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30108-4","article-title":"EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis","volume":"4","author":"Luft","year":"2017","journal-title":"Lancet Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12071022","article-title":"EASIX, Modified EASIX and Simplified EASIX as an early predictor for intensive care unit admission and mortality in severe COVID-19 patients","volume":"12","author":"Zi\u0144czuk","year":"2022","journal-title":"J Pers Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4097\/kja.21209","article-title":"Receiver operating characteristic curve: overview and practical use for clinicians","volume":"75","author":"Nahm","year":"2022","journal-title":"Korean J Anesthesiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02489-8","article-title":"The EASIX score as a predictor of sinusoidal obstruction syndrome and nonrelapse mortality in paediatric patients receiving allogeneic haematopoietic stem cell transplantation","volume":"60","author":"Muratore","year":"2025","journal-title":"Bone Marrow Transpl"},{"key":"B18","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jtct.2024.03.026","article-title":"Evaluation of circulating endothelial cells as direct marker of endothelial damage in allo-transplant recipients at high risk of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"30","author":"Farina","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.238790","article-title":"Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel","volume":"106","author":"Jiang","year":"2021","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0703-1","article-title":"EASIX and mortality after allogeneic stem cell transplantation","volume":"55","author":"Luft","year":"2020","journal-title":"Bone Marrow Transpl"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1742467\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:21:45Z","timestamp":1771928505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1742467\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":20,"alternative-id":["10.3389\/fonc.2026.1742467"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1742467","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"article-number":"1742467"}}